GlobeImmune Announces Appointment of J. William Freytag, Ph.D to Its Board of Directors

LOUISVILLE, CO--(Marketwire - March 25, 2008) - GlobeImmune, Inc. announced today the addition of J. William Freytag, Ph.D. to its Board of Directors.

"Dr. Freytag brings over 25 years of research, product development and commercialization experience to the Board," said Timothy C. Rodell M.D., GlobeImmune's Chief Executive Officer. "His recent experience as Chairman and CEO of Myogen and Aspreva Pharmaceuticals, biotechnology companies with preclinical, clinical and sales and marketing capabilities, will be invaluable to us as the company continues to grow."

Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Aspreva Pharmaceuticals Company from July 2007 through December 2007 when Aspreva was acquired by Galenica for approximately $915 million. He held the same positions with Myogen, Inc. from July 1998 until November 2006 when Myogen was acquired by Gilead Sciences for approximately $2.5 billion. Dr. Freytag currently serves on the Board of Directors for Sierra Neuropharmaceuticals, ARCA Discovery, AlphaSniffer and Immunicon. Dr. Freytag has held senior executive roles in a number of capacities at companies such as Somatogen, Inc., a biopharmaceutical company where he was responsible for corporate and commercial development and at Boehringer Mannheim Corporation where he served as President of Research and Development. Dr. Freytag spent 10 years with DuPont Medical Products in various research and business positions. He earned his Ph.D. in biochemistry from the University of Kansas Medical Center.

About GlobeImmune, Inc.

GlobeImmune is a private Colorado-based company developing active immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. The Company's lead oncology program, GI-4000, is designed to be a treatment for cancers of the lung and gastrointestinal tract. A randomized, placebo-controlled phase 2 trial in patients with resectable pancreas cancer in combination with adjuvant gemcitabine is ongoing. The Company's lead infectious disease candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection. GI-5005 is designed to complement both the current and emerging standard of care for hepatitis C infection through the direct elimination of chronically infected cells. A randomized phase 2 study of GI-5005 in combination with standard of care for patients with chronic hepatitis C infection is currently ongoing.

For additional information, please visit the company's website at www.globeimmune.com